3E Bioventures Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 56
- Portfolio
- 34
- Exits
- 13
3E Bioventures Capital General Information
Description
3E Bioventures Capital is a healthcare focused venture capital firm based in Beijing, China. The firm seeks to make investments in the drug, device, diagnostics, healthcare information technology and medical services sectors.
Contact Information
Website
Year Founded
2015
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- Suite 701, Tower C, Tsinghua Science Park
- Number 1 Zhongguancun East Road
- Beijing, Haidian 100084
- China
+86 010 0000 0000
3E Bioventures Capital Investments (56)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Cardea Bio | 12-Jan-2021 | Later Stage VC | 0000 | Other Healthcare Technology Systems | Generating Revenue | |
| 000000 000000 | 07-Jan-2021 | 00000 00000 | 000.00 | Other Healthcare Technology Systems | Generating Revenue | |
| 000000 0000000 | 19-Nov-2020 | 00000 00000 | 000.00 | Other Healthcare Technology Systems | Generating Revenue | 000 000 |
| 00000 000000000 | 18-Nov-2020 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - General | 00000 000 00.0 |
| 0000000000 | 15-Sep-2020 | 00000 00000 | 00000 | Biotechnology | Generating Revenue | |
| 0000000000 | 09-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 3 | 00000 000 00.0 |
| 000 00000000000 | 26-Aug-2020 | 00000 00000 | 000.00 | Biotechnology | Profitable | |
| 00 000000000000 | 29-May-2020 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue/Not Profitable | |
| Purinomia Biotech | 07-May-2020 | Early Stage VC | 00.000 | Biotechnology | Generating Revenue | |
| Chigene | 14-Apr-2020 | Later Stage VC | Decision/Risk Analysis | Generating Revenue |
3E Bioventures Capital Exits (13)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| OncoImmune | 23-Nov-2020 | Merger/Acquisition | 00000 |
| 00 000000000000 | 02-Oct-2020 | 000 | 00000 |
| 000000 000000000 | 24-Sep-2020 | 000000000000000000 | |
| 000000000 | 29-Jul-2020 | 000 | 00000 |
| 00000 0000000000 | 31-Oct-2018 | 000 | 0000 |
| 0000000 00000000'0 | 22-Sep-2018 | 000000000000000000 | 000.00 |
| 00000000 000000000 | 06-Jul-2016 | 000000000000000000 | |
| 000000000 | 06-Jan-2016 | 000 | |
| BGI Tech | 14-Jan-2015 | Merger of Equals | |
| Chiral Quest | Secondary Transaction - Open Market |
3E Bioventures Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trial3E Bioventures Capital Team (9)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Lue Sun | President | 0 | Beijing, China | ||
| Karen Liu Ph.D | Founding Partner | 00 | 0 | 0 | Beijing, China |
| Joy Yang Ph.D | Venture Partner | Beijing, China | |||
| Francine Fang Ph.D | Partner | 0 | Beijing, China | ||
| Hao Zhou | Partner | Beijing, China |
3E Bioventures Capital Co-Investors (124)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| ShangBay Capital | 3 | 0 |
|
|
|
| Tsingyuan Ventures | 0 | 0 |
|
|
|
| Bay City Capital | 0 | 0 |
|
|
|
| Cowin Capital | 0 |
|
|
||
| Northern Light Venture Capital | 0 | 0 |
|
|